Citations

Clear

1053 citation(s) found for "Andre, F".

Genetic Disruption of Kir6.2, the Pore-Forming Subunit of ATP-Sensitive K+ Channel, Predisposes to Catecholamine-Induced Ventricular Dysrhythmia
Liu, Xiaoke , Kane, Garvan C. , Alekseev, Alexey E., Hodgson, Denice M., O’Cochlain, Fearghas, Seino, Susumu , Yamada, Satsuki , Jahangir, Arshad , Miki, Takashi , Terzic, André , Liu, Xiaoke

Mayo Clinic

Diabetes | March 6, 2007 | Volume: 53 | Issue: suppl_3 | Pages: S165-S168

10.2337/diabetes.53.suppl_3.s165 | PMID 15561906 Get It

Metabolic-sensing ATP-sensitive K+ channels (KATP channels) adjust membrane excitability to match cellular energetic demand. In the heart, KATP channel activity has been linked to homeostatic shortening of the action potential under stress, yet the requirement of channel function in securing cardiac electrical stability is only partially understood. Here, upon catecholamine challenge, disruption of KATP channels, by genetic deletion of the pore-forming Kir6.2 subunit, produced defective cardiac action potential shortening, predisposing the myocardium to early afterdepolarizations. This deficit in repolarization reserve, demonstrated in Kir6.2-knockout hearts, translated into a high risk for induction of triggered activity and ventricular dysrhythmia. Thus, intact KATP channel function is mandatory for adequate repolarization under sympathetic stress providing electrical tolerance against triggered arrhythmia.
Cardiopoietic programming of embryonic stem cells for tumor-free heart repair
Behfar, Atta , Pérez-Terzic, Carmen, Faustino, Randolph S. , Arrell, D. Kent , Hodgson, Denice M., Pucéat, Michel , Niederländer, Nicolas J. , Alekseev, Alexey E., Zingman, Leonid V. , Yamada, Satsuki , Terzic, André , Behfar, Atta

Mayo Clinic

The Journal of Experimental Medicine | February 6, 2007 | Volume: 204 | Issue: 2 | Pages: 405-420

10.1084/jem.20061916 | PMID 17283208 Get It

Embryonic stem cells have the distinct potential for tissue regeneration, including cardiac repair. Their propensity for multilineage differentiation carries, however, the liability of neoplastic growth, impeding therapeutic application. Here, the tumorigenic threat associated with embryonic stem cell transplantation was suppressed by cardiac-restricted transgenic expression of the reprogramming cytokine TNF-α, enhancing the cardiogenic competence of recipient heart. The in vivo aptitude of TNF-α to promote cardiac differentiation was recapitulated in embryoid bodies in vitro. The procardiogenic action required an intact endoderm and was mediated by secreted cardio-inductive signals. Resolved TNF-α–induced endoderm-derived factors, combined in a cocktail, secured guided differentiation of embryonic stem cells in monolayers produce cardiac progenitors termed cardiopoietic cells. Characterized by a down-regulation of oncogenic markers, up-regulation, and nuclear translocation of cardiac transcription factors, this predetermined population yielded functional cardiomyocyte progeny. Recruited cardiopoietic cells delivered in infarcted hearts generated cardiomyocytes that proliferated into scar tissue, integrating with host myocardium for tumor-free repair. Thus, cardiopoietic programming establishes a strategy to hone stem cell pluripotency, offering a tumor-resistant approach for regeneration.
Gene knockout of the KCNJ8‐encoded Kir6.1 K ATP channel imparts fatal susceptibility to endotoxemia
Kane, Garvan C. , Lam, Chen‐Fuh , O’Cochlain, Fearghas, Hodgson, Denice M., Reyes, Santiago , Liu, Xiaoke , Seino, Susumu , Katušić, Zvonimir S. , Miki, Takashi , Terzic, André , Liu, Xiaoke

Mayo Clinic

The FASEB Journal | October 31, 2006 | Volume: 20 | Issue: 13 | Pages: 2271-2280

10.1096/fj.06-6349com | PMID 17077304 Get It

Sepsis, the systemic inflammatory response to infection, imposes a high demand for bodily adaptation, with the cardiovascular response a key determinant of outcome. The homeostatic elements that secure cardiac tolerance in the setting of the sepsis syndrome are poorly understood. Here, in a model of acute septic shock induced by endotoxin challenge with Escherichia coli lipopolysaccharide (LPS), knockout of the KCNJ8 gene encoding the vascular Kir6.1 K ATP channel pore predisposed to an early and profound survival disadvantage. The exaggerated susceptibility provoked by disruption of this stress‐responsive sensor of cellular metabolism was linked to progressive deterioration in cardiac activity, ischemic myocardial damage, and contractile dysfunction. Deletion of KCNJ8 blunted the responsiveness of coronary vessels to cytokine‐ or metabolic‐mediated vasodilation necessary to support myocardial perfusion in the wild‐type (WT), creating a deficit in adaptive response in the Kir6.1 knockout. Application of a K ATP channel opener drug improved survival in the endotoxic WT but had no effect in the Kir6.1 knockout. Restoration of the dilatory capacity of coronary vessels was required to rescue the Kir6.1 knockout phenotype and reverse survival disadvantage in lethal endotoxemia. Thus, the Kir6.1containing K ATP channel, by coupling vasoreactivity with metabolic demand, provides a vital feedback element for cardiovascular tolerance in endotoxic shock.—Kane, G. C., Lam, C‐F., O'Cochlain, F., Hodgson, D. M., Reyes, S., Liu, X‐K., Miki, T., Seino, S., Katusic, Z. S., Terzic, A. Gene knockout of the KCNJ8encoded Kir6.1 KATP channel imparts fatal susceptibility to endotoxemia. FASEB J. 20, 2271–2280 (2006)
Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer
Goldberg, Richard M. , Tabah-Fisch, Isabelle, Bleiberg, Harry, Gramont, Aimery de , Tournigand, Christophe , André, Thierry , Rothenberg, Mace L., Green, Erin , Sargent, Daniel J. , Sargent, Daniel J , André, Thierry

Mayo Clinic

Journal of Clinical Oncology | August 31, 2006 | Volume: 24 | Issue: 25 | Pages: 4085-4091

10.1200/jco.2006.06.9039 | PMID 16943526 Get It

Purpose Oxaliplatin, fluorouracil, and leucovorin are commonly used to treat advanced and resected colorectal cancer. This analysis compares the safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly (FOLFOX4) in patients age younger than and at least 70 years. Patients and Methods This retrospective analysis included 3,742 colorectal cancer patients (614 age ≥ 70) from four clinical trials testing FOLFOX4 in the adjuvant, first-, and second-line settings. End points included grade ≥ 3 adverse events, response rate (in advanced disease), progression or relapse-free survival, dose-intensity, and overall survival in the studies with mature survival data. Results Grade ≥ 3 hematologic toxicity (neutropenia [43% v 49%; P = .04] and thrombocytopenia [2% v 5%; P = .04]) were significantly higher in older patients. Older age was not associated with increased rates of severe neurologic adverse events, diarrhea, nausea/vomiting, infection, overall incidence of grade ≥ 3 toxicity (63% v 67%; P = .15), or 60-day mortality (1.1% v 2.3%; P = .20). The relative benefit of FOLFOX4 versus control did not differ by age for response rate, progression or recurrence free-survival (hazard ratio, 0.70 for FOLFOX4 v control for age < 70, 0.65 for age ≥ 70; P = .42), or overall survival (hazard ratio, 0.77 age < 70, 0.82 age ≥ 70; P = .79). Dose-intensity did not differ by age at cycles 1, 3, 6, or 12. Conclusion FOLFOX4 maintains its efficacy and safety ratio in selected elderly patients with colorectal cancer. Its judicious use should be considered without regard to patient age, although scant data are available among patients older than 80 years.
Early aging–associated phenotypes in Bub3/Rae1 haploinsufficient mice
Baker, Darren J. , Jeganathan, Karthik B. , Malureanu, Liviu, Pérez-Terzic, Carmen, Deursen, Jan M. A. van, Terzic, André , Jeganathan, Karthik B , Baker, Darren J

Mayo Clinic

The Journal of Cell Biology | February 13, 2006 | Volume: 172 | Issue: 4 | Pages: 529-540

10.1083/jcb.200507081 | PMID 16476774 Get It

Aging is a highly complex biological process that is believed to involve multiple mechanisms. Mice that have small amounts of the mitotic checkpoint protein BubR1 age much faster than normal mice, but whether other mitotic checkpoint genes function to prevent the early onset of aging is unknown. In this study, we show that several aging-associated phenotypes appear early in mice that are double haploinsufficient for the mitotic checkpoint genes Bub3 and Rae1 but not in mice that are single haploinsufficient for these genes. Mouse embryonic fibroblasts (MEFs) from Bub3/Rae1 haploinsufficient mice undergo premature senescence and accumulate high levels of p19, p53, p21, and p16, whereas MEFs from single haploinsufficient mice do not. Furthermore, although BubR1 hypomorphic mice have less aneuploidy than Bub3/Rae1 haploinsufficient mice, they age much faster. Our findings suggest that early onset of aging-associated phenotypes in mice with mitotic checkpoint gene defects is linked to cellular senescence and activation of the p53 and p16 pathways rather than to aneuploidy.
Aneurysmal Bone Cyst: A Neoplasm Driven by Upregulation of the USP6 Oncogene
Oliveira, André M. , Chou, Margaret M. , Pérez‐Atayde, Antonio R. , Rosenberg, Andrew E.

Mayo Clinic

Journal of Clinical Oncology | December 28, 2005 | Volume: 24 | Issue: 1 | Pages: e1-e1

10.1200/jco.2005.04.4818 | PMID 16382110 Get It

Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials
Sargent, Daniel J. , Wieand, Harry S., Haller, Daniel G. , Gray, Richard , Benedetti, Jacqueline, Labianca, Roberto , Seitz, Jean François, O’Callaghan, Christopher J., Francini, Guido, Catalano, Paul J. , Blanke, Charles D. , Green, Erin , André, Thierry , Goldberg, Richard M. , Gramont, Aimery de , Buyse, Marc , Grothey, Axel , O’Connell, Michael J. , Kerr, David , Wolmark, Norman , Sargent, Daniel J , André, Thierry

Mayo Clinic

Journal of Clinical Oncology | October 31, 2005 | Volume: 23 | Issue: 34 | Pages: 8664-8670

10.1200/jco.2005.01.6071 | PMID 16260700 Get It

Purpose A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5 years demonstrating adequate follow-up. A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice. Methods Individual patient data were pooled from 18 randomized phase III colon cancer adjuvant clinical trials. Trials included 43 arms, with a pooled sample size of 20,898 patients. The primary hypothesis was that disease-free survival (DFS), with 3 years of follow-up, is an appropriate primary end point to replace OS with 5 years of follow-up. Results The recurrence rates for years 1 through 5 were 12%, 14%, 8%, 5%, and 3%, respectively. Median time from recurrence to death was 12 months. Eighty percent of recurrences were in the first 3 years; 91% of patients with recurrence by 3 years died before 5 years. Correlation between 3-year DFS and 5-year OS was 0.89. Comparing control versus experimental arms within each trial, the correlation between hazard ratios for DFS and OS was 0.92. Within-trial log-rank testing using both DFS and OS provided the same conclusion in 23 (92%) of 25 cases. Formal measures of surrogacy were satisfied. Conclusion In patients treated on phase III adjuvant colon clinical trials, DFS and OS are highly correlated, both within patients and across trials. These results suggest that DFS after 3 years of median follow-up is an appropriate end point for adjuvant colon cancer clinical trials of fluorouracil-based regimens, although marginally significant DFS improvements may not translate into significant OS benefits.
53BP1 Cooperates with p53 and Functions as a Haploinsufficient Tumor Suppressor in Mice
Ward, Irene M., Minn, Kay, Mueller, Melissa D., Molina, Julian R. , Yu, Xiaochun , Frisk, Craig S., Nussenzweig, André , Nussenzweig, André , Difilippantonio, Simone , Ried, Thomas , Chen, Junjie

Mayo Clinic

Molecular and Cellular Biology | October 31, 2005 | Volume: 25 | Issue: 22 | Pages: 10079-10086

10.1128/mcb.25.22.10079-10086.2005 | PMID 16260621 Get It

USP6 (Tre2) Fusion Oncogenes in Aneurysmal Bone Cyst
Oliveira, André M. , Hsi, Bae‐Li, Weremowicz, Stanislawa, Cin, Paola Dal , Joseph, Nora, Bridge, Julia A. , Fletcher, Jonathan A. , Rosenberg, Andrew E. , Pérez‐Atayde, Antonio R.

Mayo Clinic

Cancer Research | September 20, 2005 | Volume: 64 | Issue: 6 | Pages: 1920-1923

10.1158/0008-5472.can-03-2827 | PMID 15026324 Get It

Abstract Aneurysmal bone cyst (ABC) is a locally aggressive osseous lesion that typically occurs during the first two decades of life. ABC was regarded historically as a nonneoplastic process, but recent cytogenetic data have shown clonal rearrangements of chromosomal bands 16q22 and 17p13, indicating a neoplastic basis in at least some ABCs. Herein we show that a recurring ABC chromosomal translocation t(16;17)(q22;p13) creates a fusion gene in which the osteoblast cadherin 11 gene (CDH11) promoter region on 16q22 is juxtaposed to the entire ubiquitin-specific protease USP6 (Tre2) coding sequence on 17p13. CDH11-USP6 fusion transcripts were demonstrated only in ABC with t(16;17) but other ABCs had CDH11 or USP6 rearrangements resulting from alternate cytogenetic mechanisms. CDH11 is expressed strongly in bone, and our findings implicate a novel oncogenic mechanism in which deregulated USP6 transcription results from juxtaposition to the highly active CDH11 promoter.
Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer
Baron, Andre T. , Boardman, Cecelia H., Lafky, Jacqueline M., Rademaker, Alfred , Liu, Dachao, Fishman, David A. , Podratz, Karl C. , Maihle, Nita J. , Boardman, Cecelia H.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 20, 2005 | Volume: 14 | Issue: 2 | Pages: 306-318

10.1158/1055-9965.epi-04-0423 | PMID 15734951 Get It

Abstract Epithelial ovarian cancer (EOC) is the leading cause of death among all gynecologic cancers in the United States. Because women who are diagnosed with early stage disease have a better prognosis than women diagnosed with late stage disease, early detection represents a potentially practical approach to reduce the mortality associated with EOC. Unfortunately, no single screening test has proven to be effective for this purpose, and a valid and feasible screening program to detect early stage EOC in the general population has not yet been devised. Consequently, research has focused on coupling two or more screening modalities to improve program validity and feasibility. Serum cancer antigen 125 (CA125) and a soluble isoform of the epidermal growth factor receptor (p110 sEGFR) have been studied individually as biomarkers of ovarian cancer. In this study, we compare serum CA125 levels and sEGFR concentrations in women with EOC to women with benign gynecologic conditions of ovarian and non-ovarian origin. We show that serum sEGFR concentrations are lower in patients with EOC than in women with benign gynecologic conditions, whereas serum CA125 levels are higher in patients to EOC compared with women with benign gynecologic conditions. These data also reveal that age and serum sEGFR concentrations modify the association between CA125 levels and EOC versus benign gynecologic disease. Hence, age- and sEGFR-dependent CA125 cutoff thresholds improve the ability of CA125 to discern EOC patients from women with benign ovarian tumors and non-ovarian gynecologic conditions. Our analyses show that parallel testing with fixed sEGFR and CA125 cutoff thresholds optimizes sensitivity to detect EOC, whereas serial testing with age- and sEGFR-dependent CA125 cutoff thresholds optimizes test specificity, and overall accuracy to discern patients with EOC from women with benign ovarian and non-ovarian gynecologic conditions. The combined use of serologic sEGFR and CA125, thus, has improved utility for screening and diagnosing EOC, which may increase the positive predictive value of a multimodal screening program that incorporates these biomarkers to detect and subsequently differentiate benign from malignant ovarian tumors.